Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 53c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $243.82 -1.25%
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.30, $0.53 better than the analyst estimate of $4.77. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2024 EPS of $19.20-$20.30, versus the consensus of $18.51. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.1 billion, versus the consensus of $4.05 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Occidental Petroleum releases Q2 2026 earnings considerations
- Faraday Future registers up to 62M shares for resale
- What Delta’s report tells investors in American and United
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
